← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2003Last known activity
Sep 29, 2025
Timeline
1970s
- Jun 1, 1977
PATH— Founded
Drugs by trial phase (129 distinct, 139 trials)
Phase 4 (24 own, 0 via acquisition)
- mebendazole
- rotavirus vaccine, live, oral, pentavalent
- tafenoquine succinate
- primaquine
- yellow fever vaccine 17d strain
- inactivated japanese encephalitis vaccine
- attenuated measles vaccine - Edmonston strain
- inactivated influenza vaccine
- live attenuated chimeric japanese encephalitis vaccine
- measles-rubella vaccine
- chloroquine
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- monovalent group c meningococcal vaccine
- +9 more
Phase 3 (24 own, 0 via acquisition)
- gsk 257049
- inactivated rabies vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- ivermectin
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- pneumococcal 13-valent conjugate vaccine
- amphotericin b
- live attenuated influenza virus vaccine
- Haemophilus influenzae Type b Conjugate and Hepatitis B (Recombinant)
- live oral poliovirus type 1, 2 and 3
- recombinant human papillomavirus virus type 6/11 bivalent vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- sulfadoxine
- azithromycin
- dipropyltryptamine
- +9 more
Phase 2 (55 own, 0 via acquisition)
Phase 1 (20 own, 0 via acquisition)
- ic47
- montanide isa 720
- ciprofloxacin
- as03
- influenza vaccine, recombinant hemagglutinin
- nmrc-m3v-ad-pfca
- plasmodium falciparum sporozoite
- recombinant influenza hemagglutinin
- shigella flexneri 2a invaplex 50
- wrss1
- mcv-5
- msp-1 (fmp-1) with as02a
- plasmodium falciparum chimeric prot. 2.9
- streptococcus pneumoniae whole cell vaccine
- detoxified shigella flexneri 2a artificial invasin complex
- +5 more
Other trials (6 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Ancylostomiasis
- Cholera
- Communicable Diseases
- Diarrhea
- Dysentery
- Dysentery, Bacillary
- Encephalitis
- Encephalitis, Japanese
- Gastroenteritis
- Glucosephosphate Dehydrogenase Deficiency
- Henipavirus Infections
- HIV Infections
- Hookworm Infections
- Hypersensitivity
- Infections
- Influenza, Human
- Influenza in Birds
- Leishmaniasis
- Leishmaniasis, Visceral
- Malaria
- Malaria, Falciparum
- Malaria, Vivax
- Measles
- Meningitis
- Meningitis, Meningococcal
- Mumps
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Pneumococcal
- Poliomyelitis
- Rhinitis
- Rotavirus Infections
- Rubella
- Streptococcal Infections
- Uterine Cervical Neoplasms
- Virus Diseases
Recent trials (50)
- NCT06895486Lead sponsorPhase 2Sep 29, 2025
- NCT06879327Lead sponsorPhase 2May 30, 2025
- NCT06765863CollaboratorN/AJan 16, 2025
- NCT06611371CollaboratorPhase 1/Phase 2Oct 31, 2024
- NCT06516042Lead sponsorPhase 3Aug 21, 2024
- NCT06516042OfficialPhase 3Aug 21, 2024
- NCT05959616CollaboratorPhase 1Mar 1, 2024
- NCT06137664Lead sponsorPhase 1/Phase 2Dec 29, 2023
- NCT05961059CollaboratorPhase 1Nov 30, 2023
- NCT06077656CollaboratorPhase 2Oct 25, 2023
- NCT05654467Lead sponsorPhase 2May 29, 2023
- NCT05644184Lead sponsorPhase 2Feb 28, 2023
- NCT05540028CollaboratorPhase 1/Phase 2Sep 28, 2022
- NCT04992520Lead sponsorPhase 1Feb 21, 2022
- NCT04704999CollaboratorPhase 4Oct 1, 2021
Details
- Founded
- Seattle, WA, US Jun 1, 1977
- Last known activity
- Sep 29, 2025